edaravone
Sign in to saveAlso known as developer Z, C.I. developer 1, norphenazone, 3-methyl-1-phenyl-2-pyrazolin-5-one, 3-methyl-1-phenyl-5-pyrazolone, 3-methyl-1-phenylpyrazol-5-one, methylphenylpyrazolone, phenylmethylpyrazolone
Edaravone, sold under the brand name Radicava among others, is a medication used to treat stroke and amyotrophic lateral sclerosis (ALS). It is given by intravenous infusion and by mouth.
Key facts
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 443718859
- Drug.image
- Edaravone Structural Formula V1.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 160
- Drug.image2
- Edaravone ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Radicava, others
- Drug.MedlinePlus
- a617027
- Drug.DailyMedID
- Edaravone
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- Intravenous, by mouth
- Drug.ATC_prefix
- N07
- Drug.ATC_suffix
- XX14
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_status
- Rx-only
via Wikipedia infobox
Research
2,015 papers- Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.Stroke · 2021
- Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.Acta neurologica Belgica · 2024
- Edaravone May Prevent Ferroptosis in ALS.Current drug targets · 2020
- Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.Medicinal research reviews · 2019
- Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.JAMA neurology · 2022
via PubMed
Wikidata facts
- Mass
- 174.079
Show 5 more facts
- Commons category
- Edaravone
- chemical formula
- C₁₀H₁₀N₂O
- canonical SMILES
- CC1=NN(C(=O)C1)C2=CC=CC=C2
- NCI Thesaurus ID
- C74323
- melting point
- 129
Sources (7)
via Wikidata · CC0
~6 min read
Article
12 sectionsContents
- Medical uses
- Adverse effects
- Pharmacology
- History
- Re-analyses of efficacy
- New formulations
- Combination formulations
- Society and culture
- Economics
- Brand names
- References
- Further reading
Edaravone, sold under the brand name Radicava among others, is a medication used to treat stroke and amyotrophic lateral sclerosis (ALS). It is given by intravenous infusion and by mouth.
The mechanism by which edaravone might be effective is unknown. The medication is known to be an antioxidant, and oxidative stress has been hypothesized to be part of the process that kills neurons in people with ALS and in stroke victims.